SIGA — SIGA Technologies Inc · catalysts, narrative & risks

SIGA Technologies Inc. (SIGA) — As of 2026-10-31

Company snapshot: SIGA Technologies, Inc. (Nasdaq: SIGA) is a commercial-stage pharmaceutical company based in New York, focused on health security and infectious-disease countermeasures, with its lead product TPOXX (tecovirimat) — an oral (and IV) antiviral for smallpox and other orthopoxviruses [1], [5], [27]. CEO is Dr. Diem Nguyen and CFO is Daniel Luckshire [1]. As of Oct 30, 2026, Yahoo Finance shows a market cap of ~$218.4M intraday, a prior close of $3.18, a 52-week range of $2.83–$8.46, TTM revenue of $53.66M, TTM net income of -$2.79M, total cash of $117.58M, and a "Bearish" Motley Fool rating [22], [23]. (Note: the internal on-file market cap of ~$228.48M as of Oct 29 differs slightly from the intraday figure; the discrepancy likely reflects ordinary daily price movement.)